Global Biosimilars Monoclonal Antibodies Market Set To Grow To $5.9bn By 2023

02 August 2018
Pharma

Visiongain’ has launched a new pharma report Biosimilar Monoclonal Antibodies Market Report : Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

Biosimilar monoclonal antibodies (mAbs) form an emerging sector in pharmaceuticals. As patents for some of the industry’s top-selling biological drugs (biologics) expire, companies have chosen to invest in the development of biosimilars. The result is an R&D pipeline holding at least 86 biosimilar mAb candidates. Emerging markets with less stringent regulatory processes, such as India and Russia, dominated shares of the market in 2017. However, in addition to China, the more developed markets of the US and the EU5 will increase their market shares throughout the forecast period as patents expire on the originator products.

The lead analyst of the report commented “The biosimilar mAbs market will face challenges posed by competition from biobetters and a lack of confidence of some clinicians in biosimilar interchangeability. However, these challenges will be overcome owing to the high demand worldwide for affordable biological drugs, especially therapeutic monoclonal antibodies. Visiongain expects governmental policy to increase preferences for the use of biosimilars mAbs over branded ones as healthcare budgets become increasingly strained. Biosimilar mAbs will therefore have an important, rising role to play in healthcare systems from 2016 to 2028.”

Leading companies featured in the report include BIOCAD, Biocon, BioXpress, Celltrion, Coherus Biosciences, Gene Techno Science, Genor Biopharma, Harvest Moon, Hospira, Mabion, Pfizer, Samsung Bioepsis

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever